* Novo says diabetes drug Levemir efficient in children
* Says now working to update Levemir label
* Shares rise 0.3 percent vs flat Copenhagen bourse
(Adds details, quote, share price)
COPENHAGEN, March 23 (Reuters) - Denmark’s Novo Nordisk (NOVOb.CO) said on Wednesday that new clinical trial data supported the use of its diabetes drug Levemir in children aged two to five years.
The world’s biggest maker of insulin said the treatment had shown lower hypoglycaemic risks, and that the group was now working to update the Levemir label.
Hypoglycaemia is a state produced by lower than normal levels of blood sugar.
“No patients treated with Levemir had a severe hypoglycaemic episode, whereas there were six reported episodes in three patients treated with human basal insulin,” Novo said in the statement.
“If our application for a label update is successful, Levemir will be the first basal insulin analogue with an indication extended to this very young patient population,” Kirstine Frandsen, chief of global medical affairs at Novo Nordisk said in the statement.
Shares in Novo Nordisk rose 0.3 percent at 0930 GMT, outperforming the Copenhagen bourse's bluechip index .OMXC20 which traded flat. (Reporting by Mette Fraende; Editing by Louise Heavens)